SNTI

Senti Biosciences Holdings, Inc.

0.40 USD

Last updated Aug 27, 05:46 UTC

Yesterday HIGH

$0.4

Yesterday LOW

$0.37

52w HIGH

$2.88

52w LOW

$0.33

EPS

-0.41

PE

-0.97

Next Earnings

Nov 12, 2026

Overview News Government Trades Fundamentals

Senti Biosciences Holdings, Inc. stock is up 5% since 30 days ago. The next earnings date is Nov 12, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 August’s closed higher than July.

Webmaster

Wed Jul 15, 2026

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk

Wed Jul 15, 2026

Senti Biosciences Signs Agreement To Sell Assets Related To Its Gene-Circuit-Enabled Pipeline To Celadon For Up To $60M In Milestone Payments Over Seven Years

Senti Biosciences Holdings, Inc. (NASDAQ: SNTI) ("SBH" or the "Company") today announced a strategic transaction designed to sharpen its focus on next-generation controllable genetic medicines powered by
Webmaster

Wed Jul 15, 2026

Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending
Benzinga Newsdesk

Fri May 15, 2026

Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and raises the price target from $11 to $12.
Benzinga Newsdesk

Thu May 14, 2026

Senti Biosciences Q1 EPS $(0.14) Beats $(0.36) Estimate, Sales $16.000K

Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.36) by 61.11 percent. This is a 90.07 percent increase over losses of $(1.41) per share from
Benzinga Newsdesk

Thu May 14, 2026

Senti Biosciences Announces Completion Of Type B Initial Comprehensive Multidisciplinary RMAT Meeting With FDA Regarding SENTI-202, Logic Gated Off-The-Shelf CAR-NK Cell Therapy For R/R AML And Updated Phase 1 Clinical Data

Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable
Benzinga Newsdesk

Mon May 4, 2026

Senti Biosciences Holdings shares are trading lower after the company announced it entered into a $40 million convertible note financing agreement with Celadon Affiliate.
Benzinga Newsdesk

Fri May 1, 2026

Senti Biosciences Enters Up To $40M Convertible Note Financing Agreement With Celadon Affiliate

Securities Purchase Agreement On April 27, 2026, Senti Biosciences Holdings, Inc. (the "Company"), Senti Holdings, Inc., a direct, wholly owned subsidiary of the Company ("Senti Holdings"), and Senti Biosciences,
Benzinga Newsdesk

Wed Apr 1, 2026

Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026; Upon Effectiveness Of Holding Company Reorganization, Senti Biosciences Holdings Would Become Successor Issuer To Co

Other Events On April 1, 2026, Senti Biosciences, Inc. (the "Company") announced plans to implement a holding company reorganization (the "Holding Company Reorganization"), currently planned to become effective by
Benzinga Newsdesk

Wed Apr 1, 2026

Senti Biosciences Publishes New Peer-Reviewed Research In Cell Systems Demonstrating Its Systematic Framework For Engineering NOT-Gated Chimeric Antigen Receptor Circuits In Both T Cells And Natural Killer Cells

Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the publication

CRWD $210.28 USD

KLAC $183.75 USD

AUPH $16.54 USD

CCXI CCXI $14.79 USD

CRM $231.70 USD

AVGO $355.31 USD

NLST NLST $0.00 USD